SEC Form 4 · accession 0001771961-26-000006
Arcus Biosciences, Inc. · RCUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexander Azoy
Officer — Chief Accounting Officer
Period of report
Aug 21, 2026
Accepted (ET)
Aug 24, 2026 · 5:52 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001724521
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 21, 2026 | M | 2,827 | $15.44 | A | 42,408 | D | |
| Common StockF1,F2 | Aug 21, 2026 | S | 2,827 | $30.00 | D | 39,581 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F3 | $15.44 | Aug 21, 2026 | M | 2,827 | D | — | Jan 22, 2034 | Common Stock | 2,827 | 3,073 | D |
Explanation of responses
- F1The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2Includes the unvested portion of the Reporting Person's RSU grants.
- F3The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company.